ECSP099673A - Formas sólidas de un inhibidor de cinasa raf - Google Patents

Formas sólidas de un inhibidor de cinasa raf

Info

Publication number
ECSP099673A
ECSP099673A EC2009009673A ECSP099673A ECSP099673A EC SP099673 A ECSP099673 A EC SP099673A EC 2009009673 A EC2009009673 A EC 2009009673A EC SP099673 A ECSP099673 A EC SP099673A EC SP099673 A ECSP099673 A EC SP099673A
Authority
EC
Ecuador
Prior art keywords
solid forms
raf
inhibitor
cinase
methyl
Prior art date
Application number
EC2009009673A
Other languages
English (en)
Inventor
Augustus Okhamafe
Ahmad Hashash
Kangwen L Lin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP099673A publication Critical patent/ECSP099673A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a las formas sólidas del inhibidor de cinasa Raf de 1-metil-5-(2-(5-(trifluoro-metil)-1H-imidazol-2-il)-piridin-4-iloxi)-N-(4-(trifluoro-metil)-fenil)-1H-benzo-[d]-imidazol-2-amina, así como a composiciones de las mismas y a la utilización de las mismas.
EC2009009673A 2007-03-02 2009-10-02 Formas sólidas de un inhibidor de cinasa raf ECSP099673A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90445507P 2007-03-02 2007-03-02

Publications (1)

Publication Number Publication Date
ECSP099673A true ECSP099673A (es) 2009-11-30

Family

ID=39456506

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009673A ECSP099673A (es) 2007-03-02 2009-10-02 Formas sólidas de un inhibidor de cinasa raf

Country Status (25)

Country Link
US (1) US8324389B2 (es)
EP (1) EP2132198A1 (es)
JP (1) JP2010520215A (es)
KR (1) KR20090117833A (es)
CN (1) CN101679372A (es)
AR (1) AR065565A1 (es)
AU (1) AU2008251764B2 (es)
BR (1) BRPI0808526A2 (es)
CA (1) CA2678335A1 (es)
CL (1) CL2008000616A1 (es)
CO (1) CO6230987A2 (es)
EC (1) ECSP099673A (es)
GT (1) GT200900237A (es)
IL (1) IL200441A0 (es)
MA (1) MA31259B1 (es)
MX (1) MX2009009344A (es)
MY (1) MY148438A (es)
NZ (1) NZ579084A (es)
PE (1) PE20081801A1 (es)
RU (1) RU2483064C2 (es)
SG (1) SG179423A1 (es)
TN (1) TN2009000356A1 (es)
TW (1) TW200846341A (es)
WO (1) WO2008140850A1 (es)
ZA (1) ZA200905618B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008256922B2 (en) * 2007-05-23 2011-07-28 Novartis Ag Raf inhibitors for the treatment of thyroid cancer
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
JP6768716B2 (ja) * 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
RU2693004C1 (ru) * 2019-03-15 2019-07-01 Лейсан Фаридовна Минигулова Противоопухолевая композиция цисплатина с ингибитором 6-фосфоглюконатдегидрогеназы

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
MXPA04009541A (es) * 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
BRPI0715423A2 (pt) * 2006-07-21 2013-07-02 Novartis Ag formulaÇÕes para Éteres de benzimidazolil piridila
PE20130814A1 (es) * 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Also Published As

Publication number Publication date
TW200846341A (en) 2008-12-01
IL200441A0 (en) 2010-04-29
MX2009009344A (es) 2009-09-11
SG179423A1 (en) 2012-04-27
BRPI0808526A2 (pt) 2014-08-19
CL2008000616A1 (es) 2008-09-12
ZA200905618B (en) 2010-05-26
PE20081801A1 (es) 2009-01-08
US8324389B2 (en) 2012-12-04
CO6230987A2 (es) 2010-12-20
EP2132198A1 (en) 2009-12-16
AU2008251764B2 (en) 2012-09-13
CN101679372A (zh) 2010-03-24
MA31259B1 (fr) 2010-03-01
JP2010520215A (ja) 2010-06-10
NZ579084A (en) 2012-04-27
CA2678335A1 (en) 2008-11-20
AR065565A1 (es) 2009-06-17
MY148438A (en) 2013-04-30
RU2009136308A (ru) 2011-04-10
KR20090117833A (ko) 2009-11-12
WO2008140850A1 (en) 2008-11-20
TN2009000356A1 (en) 2010-12-31
AU2008251764A1 (en) 2008-11-20
RU2483064C2 (ru) 2013-05-27
GT200900237A (es) 2010-06-24
US20100209418A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
ECSP077981A (es) Formas polimórficas del éster etílico del ácido 3-[(2-{[4-(hexiloxicarbonilamino- imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il- amino]-propiónico
BRPI0815715A2 (pt) compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases.
LTPA2019005I1 (lt) Junginiai ir kompozicijos, kaip proteinkinazės inhibitoriai
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
CL2012001221A1 (es) Compuestos derivados de 4 -(1h-pirrol-1-il) pirimidin -2-ilamino y 4 -(1h-pirazol-1-il)- pirimidin-2-ilamino, inhibidores de quinasa; un compuesto isomerico; composicion farmaceutica; utiles en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, colitis ulcerante, enfermedad de crohn, bronquitis, dermatitis, entre otras.
NI201000098A (es) 4-fenilpiran-3,5-dionas, 4-feniltiopiran-3,5-dionas y 2-fenilciclohexan-1,3,5-trionas como herbicidas.
UA111725C2 (uk) Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
ATE500232T1 (de) Kristalline form von 2-chlor-5-ä3,6-dihydro-3- methyl-2,6-dioxo-4-(trifluormethyl)-1-(2h)- pyrimidinylü-4-fluor-n-äämethyl-(1- methylethyl)aminoüsulfonylübenzamid
CO6801792A2 (es) Formas cristalinas de 5-cloro-n2-(2-isoporpoxi 5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina.
CL2010001608A1 (es) Compuestos derivados de 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-4,5-dihidro-2h-isoquinolin-1-ona y 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-3,4-dihidro-2h-isoquinolin-1-ona, inhibidores de quinasa; composicion farmaceutica; utiles en el tratamiento de estados patologicos inflamatorios y/o inmunes.
HUE041725T2 (hu) (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
BRPI0811517A2 (pt) Compostos e composições como inibidores de c-kit e pdgfr cinase.
UA106880C2 (uk) Нові гербіциди
GT200900237A (es) Formas solidas de un inhibidor de cinasa raf.-
CY1111701T1 (el) Υδροχλωρικο αλας του 5-[3-(3-υδροξυφαινοξυ)αζετιδιν-1-υλ]-5-μεθυλ-2,2-διφαινυλεξαναμιδιου
EA201000069A1 (ru) Новые гербициды
BR112017017317A2 (pt) Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4- (etoxioxalilamino)-2-hidroximetil-2-metilpentanóico como inibidor de neprilisina
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
EP2373636A4 (en) INHIBITORS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK1)
DK3408260T3 (da) Krystallinsk (2s,4r)-5-(5'-chlor-2-fluor-[1,1'-biphenyl]-4-yl)-2-(ethoxy¬methyl)-4-(3-hydroxyisoxazol-5-carboxamido)-2-methylpentansyre og anvendelser deraf
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина